Artificial intelligence learns to recognize subtle biochemical features of γ-secretase substrates. Screening potential transmembrane proteins identifies 250 substrates, including 160 novel ones. These ...

In Alzheimer’s disease, some microglia gather around plaques, while others seem aloof, opting to keep their distance. In the July 14 Nature Neuroscience, scientists led by Marco Prinz at the ...

Eight months after Eli Lilly reported that a more gradual titration for donanemab nearly halved the risk of ARIA-E, the U.S. Food and Drug Administration has given the modification the green light.

Why do some people age rapidly while others maintain their health well into their 80s and 90s? A new study suggests that maintaining “youthful” organs may be key. Scientists led by Tony Wyss-Coray at ...

κWhen microglia wind up with a belly full of lipid droplets, it’s a sign that the cells are rallying, perhaps in vain, to a neurodegenerative threat. But according to a study published July 10 in Cell ...

Discover a comprehensive list of brain banks worldwide, facilitating Alzheimer's and Parkinson's research on Alzforum.

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...